Abstract
The term nonalcoholic steatohepatitis (NASH) has recently been proposed to identify a fatty liver disease accompanied by diffuse fatty infiltration and inflammation. However, no drug therapy has been established for NASH as yet. In the present study, we demonstrate the effect of the angiotensin II type 1 receptor antagonist telmisartan on the development of NASH in a rat model. Telmisartan, but not the angiotensin receptor antagonist valsartan, markedly attenuated hepatic steatosis, inflammation, and fibrosis in these rats. The quantitative parameters of steatosis, inflammation, and fibrosis were also ameliorated by treatment with telmisartan. Compared with telmisartan, the peroxisome proliferator-activated receptor-γ agonist pioglitazone attenuated hepatic steatosis and fibrosis of the liver to a similar degree. However, telmisartan, but not pioglitazone, dramatically decreased both subcutaneous and visceral fat. In conclusion, these results indicated that telmisartan should be the drug of first choice for the treatment of patients with NASH.
Similar content being viewed by others
References
Angulo P (2002) Nonalcoholic fatty liver disease. N Engl J Med 346:1221–1231
Farrell GC (2003) Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region? J Gastroenterol Hepatol 18:124–138
Diehl AM, Goodman Z, Ishak KG (1988) Alcohollike liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. Gastroenterology 95:1056–1062
Ludwig J, Viggiano TR, McGill DB, Oh BJ (1980) Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55:434–438
Harrison SA, Kadakia S, Lang KA, Schenker S (2002) Nonalcoholic steatohepatitis: what we know in the new millennium. Am J Gastroenterol 97:2714–2724
Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW (1990) The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 11:74–80
Fan JG, Zhong L, Xu ZJ, Tia LY, Ding XD, Li MS, Wang GL (2003) Effects of low-calorie diet on steatohepatitis in rats with obesity and hyperlipidemia. World J Gastroenterol 9:2045–2049
Miele L, Gabrieli ML, Forgione A, Vero V, Gallo A, Capristo E, Gasbarrini G, Grieco A (2006) Oxidative stress in metabolic syndrome and nonalcoholic steatohepatitis. Is it possible a role for vitamins in clinical practice? Recent Prog Med 97:1–5
Schupp M, Lee LD, Frost N, Umbreen S, Schmidt B, Unger T, Kintscher U (2006) Regulation of peroxisome proliferator-activated receptor γ activity by losartan metabolites. Hypertension 47:586–589
Sugimoto K, Qi NR, Kazdova L, Pravenec M, Ogihara T, Kurtz TW (2006) Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension 47:1003–1009
Yoshiji H, Kuriyama S, Yoshii J, Fukui H (2001) Angiotensin-α type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 34:745–750
Yokohama S, Yoneda M, Haneda M, Okamoto S, Okada M, Aso K, Hasegawa T, Tokusashi Y, Miyokawa N, Nakamura K (2004) Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 40:1222–1225
Nakae D (1999) Endogenous liver carcinogenesis in the rat. Pathol Int 49:1028–1042
Sakaida I, Okita K (2006) The role of oxidative stress in NASH and fatty liver model. Hepatol Res 33:128–131
Kawaguchi K, Sakaida I, Tsuchiya M, Omori K, Takami T, Okita K (2004) Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesion in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. Biochem Biophys Res Commun 315:187–195
Bohm M, Lee M, Kreutz R, Schinke M, Djavidani B, Wagner J, Kaling M, Wienen W, Bader M (1995) Angiotensin II receptor blockade in TGR (mREN2)27: effects of renin- angiotensin-system gene expression and cardiovascular functions. J Hypertens 13:891–899
Sahai A, Malladi P, Pan X, Paul R, Melin-Aldana H, Green RM, Whitington PF (2004) Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin. Am J Physiol Gastrointest Liver Physiol 287:1035–1043
Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680–685
Maniatis T, Fritch EF, Sambrook J (1982) Gel electrophoresis. In: Molecular cloning: A laboratory manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, pp 161–175
Rennard SI, Berg R, Martin GR, Foidart JM, Robey PG (1980) Enzyme-linked immunoassay (ELISA) for connective tissue components. Anal Biochem 104:205–214
Moshage H, Casini A, Lieber CS (1990) Acetaldehyde selectively stimulates collagen production in cultured rat liver fat-storing cells but not in hepatocytes. Hepatology 12:511–518
Chen Y, Hozawa S, Sawamura S, Sato S, Fukuyama N, Tsuji C, Mine T, Okada Y, Tanino R, Ogushi Y, Nakazawa H (2005) Deficiency of inducible nitric oxide synthase exacerbates hepatic fibrosis in mice fed high-fat diet. Biochem Biophys Res Commun 326:45–51
Niu XL, Yang X, Hoshiai K, Tanaka K, Sawamura S, Koga Y, Nakazawa H (2001) Inducible nitric oxide synthase deficiency does not affect the susceptibility of mice to atherosclerosis but increases collagen content in lesions. Circulation 103:1115–1120
Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA (1994) Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 107:1103–1109
Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW (1990) The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 11:74–80
Kawai T, Takei I, Oguma Y, Ohashi N, Tokui M, Oguchi S, Katsukawa F, Hirose H, Shimada A, Watanabe K, Saruta T (1999) Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes. Metabolism 48:1102–1107
Rasouli N, Raue U, Miles LM, Lu T, Di Gregorio GB, Elbein SC, Kern PA (2005) Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue. Am J Physiol Endocrinol Metab 288:E930–934
Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K, Umesono K, Akanuma Y, Horikoshi H, Yazaki Y, Kadowaki T (1998) Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 101:1354–1361
Kurtz TW, Pravenec M (2004) Antidiabetic mechanisms of angiotensin -converting enzyme inhibitors and angiotensinα receptor antagonists: beyond the renin-angiotensin system. J Hypertens 22:2253–2261
Pershadsingh HA, Benson SC, Ho CL, Avery MA, Kurtz TW (2003) Identification of PPAR-γ activators that do not promote fluid retention and edema: implications for treating insulin resistant hypertension and the metabolic syndrome. Proceedings of the Endocrine Society Symposium on Nuclear Receptors in Cardiovascular Disease. Hot Topics in Endocrinology 29–35
Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW (2004) Identification of telmisartan as a unique angiotensin α receptor antagonist with selective PPAR-γ-modulating activity. Hypertension 43:993–1002
Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270:12953–12956
Rosen ED, Spiegelman BM (2001) PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 276:37731–37734
Nakajima A, Wada K, Miki H, Kubota N, Nakajima N, Terauchi Y, Ohnishi S, Saubermann LJ, Kadowaki T, Blumberg RS, Nagai R, Matsuhashi N (2001) Endogenous PPAR gamma mediates anti-inflammatory activity in murine ischemia-reperfusion injury. Gastroenterology 120:460–469
Berger J, Moller DE (2002) The mechanisms of action of PPARs. Annu Rev Med 53:409–435
Picard F, Auwerx J (2002) PPAR(gamma) and glucose homeostasis. Annu Rev Nutr 22:167–197
Walczak R, Tontonoz P (2002) PPARadigms and PPARadoxes: expanding roles for PPARgamma in the control of lipid metabolism. J Lipid Res 43:177–186
Schupp M, Janke J, Clasen R, Unger T, Kintscher U (2004) Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-γ activity. Circulation 109:2054–2057
Berger JP, Petro AE, Macnaul KL, Kelly LJ, Zhang BB, Richards K, Elbrecht A, Johnson BA, Zhou G, Doebber TW, Biswas C, Parikh M, Sharma N, Tanen MR, Thompson GM, Ventre J, Adams AD, Mosley R, Surwit RS, Moller DE (2003) Distinct properties and advantages of a novel peroxisome proliferator-activated receptor γ selective modulator. Mol Endocrinol 17:662–676
Chang CY, Argo CK, Al-Osaimi AM, Caldwell SH (2006) Therapy of NAFLD: Antioxidants and cytoprotective agents. J Clin Gastroenterol 40:51–60
Comar KM, Sterling RK (2006) Review article: drug therapy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther 23:207–215
Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM (2000) Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 6:998–1003
Lieber CS, Leo MA, Mak KM, Xu Y, Cao Q, Ren C, Ponomarenko A, DeCarli LM (2004) Acarbose attenuates experimental non-alcoholic steatohepatitis. Biochem Biophys Res Commun 12:315:699–703
Nagasawa T, Inada Y, Nakano S, Tamura T, Takahashi T, Maruyama K, Yamazaki Y, Kuroda J, Shibata N (2006) Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPAR delta agonist, on development of steatohepatitis in mice fed a methionine-and choline-deficient diet. Eur J Pharmacol 536:182–191
Trappoliere M, Tuccillo C, Federico A, Di Leva A, D’Alessio C, Niosi M, Capasso R, Coppola F, Dauria M, Loguercio C (2005) The treatment of NAFLD. Eur Rev Med Pharmacol Sci 9:299–304
Acknowledgments
Supported in part by a Grant-in-aid from the Ministry of Health, Labor and Welfare of Japan to AN, by a grant from the Ministry of Education, Culture, Sports, Science and Technology of Japan Kiban-B to AN, and by a grant from the National Institute of Biomedical Innovation to AN.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fujita, K., Yoneda, M., Wada, K. et al. Telmisartan, An Angiotensin II Type 1 Receptor Blocker, Controls Progress of Nonalcoholic Steatohepatitis in Rats. Dig Dis Sci 52, 3455–3464 (2007). https://doi.org/10.1007/s10620-007-9741-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-007-9741-4